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A 2-month-old infant who had undergone orthotopic liver transplantation at the age of2 weeks 
for carbamoyl phosphate synthetase deficiency developed infection of the CNS due to Aspergillus 
jumigatus. The patient was successfully treated with administration of a combination of antifun-
gal agents (including intraventricular amphotericin B), drainage of the parletallobe abscess, and 
cessation of immunosuppression. An intraventricular catheter was used both to obtain ventricu-
lar fluid for microbiologic testing and to deliver amphotericin B during nearly 4 months of treat-
ment. We review literature on aspergillosis in solid-organ transplant recipients, especially those 
in whom the disease involves the CNS, and discuss in particular clinical presentation, diagnosis, 
treatment, and outcome. 
Superficial and systemic fungal infections relatively fre-
quently occur after solid organ transplantation. Infections due 
w Aspergillus species, which are second in frequency only 
to infections caused by Candida species, account for a 
significant proportion of these infections. The outcome of in-
fections due to Aspergillus species in solid-organ transplant 
recipients has been poor. Various clinical patterns of illness 
have been identified as prognostic markers; involvement of 
the CNS is usually fatal [1]. We report herein a favorable out-
come in the case of a 6-month-old liver transplant recipient 
",ho developed aspergillosis of the eNS. 
Case Report 
The patient was referred to Children's Hospital of Pittsburgh 
at 14 days of age: he had been diagnosed as having hyper-
ammonemia secondary to carbamoyl phosphate synthetase 
deficiency and underwent orthotopic liver transplantation the 
same day. His hospital course is summarized in figure 1. Ini-
ti,~' immunosuppressive therapy consisted of administration 
0: ~·.'cjosporine and prednisone. His early postoperative course 
was complicated by an episode of steroid-resistant rejection, 
which subsequently resolved after treatment with OKT3 
(monoclonal anti-CD3). On postoperative day 52 he devel-
oped fever, a petechial rash, and shock, and respiratory ar-
rest subsequently occurred. Ampicillin, cefotaxime, and 
amphotericin B (the latter at a dosage of 0.5 mg[kg·d)) were 
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administered empirically while the results of cultures were 
pending. After a rectal biopsy revealed evidence of cytomeg-
alovirus (CMV), he was treated with ganciclovir for 21 days 
and showed gradual improvement. The dosage of amphoteri-
cin B was increased to 1.0 mg/(kg·d) when Candida albicans 
was isolated from his blood and urine on day 14 of treatment 
with ganciclovir. He received this increased dosage of am-
photericin B for 14 days. During his convalescence from these 
infections, the patient experienced a generalized seizure that 
prompted the obtainment of a computed tomogram (CT), 
which showed a hemorrhage associated with hydrocephalus 
in the right parietal lobe. No specific explanation for the pres-
ence of the hemorrhage was identified at that time. 
On postoperative day 77 the child was diagnosed as having 
pneumonia and bacteremia due to Enterobacter cloacae. Ther-
apy with imipenem-cilastatin in combination with amikacin 
was initiated, and administration of amphotericin Band gan-
ciclovir was continued. Five days later he had a focal seizure; 
a lumbar puncture revealed 558 white blood cells (76 % neu-
trophils, 7% lymphocytes, and 17% monocytes) and 6 red 
blood cells. In the eSF, the level of protein was 188 mg/dL, 
and that of glucose was <20 mg/dL. A second CT showed 
a 2-cm enhancing ring lesion in the right parietal lobe, at the 
site of the pre\'iously identified hemorrhage. Aspiration of the 
lesion was performed on postoperative day 84; a drain was 
left in situ. Histologic examination of the contents of the ab-
scess cavity revealed branching hyphae that were consistent 
with the appearance of fungi, organisms which on culture were 
confirmed to be of the species Aspergillus Jumigatus. 
Administration of amphotericin B, which had been discon-
tinued the previous day, was resumed at a dosage of 1 
mg!(kg·d), and 5-fiuorocytosine (25 mg/kg every 6 hours) was 
added to the regimen. The drain was removed from the ab-
scess cavity 2 days later. Maintenance therapy with cyclospo-
rine and prednisone was discontinued. Intermittent iv boluses 
of steroid were utilized when rejection was biochemically evi-
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Figure 1. The immunosuppressive and 
antimicrobial therapy administered 
throughout hospitalization and the results 
of cultures performed during the weeks af-
ter transplantation are outlined. 5-FC = 
5-fluorocytosine. 
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Weeks After 
Orthotopic Liver Transplantion 
dent. An intraventricular catheter was placed for worsening 
hydrocephalus on the fourteenth day of therapy with a combi-
nation of antifungal therapy. A culture of a specimen taken 
from the catheter 4 days later was positive for Aspergillus or-
ganisms. Daily intraventricular administration of amphoteri-
cin B, beginning at a total dose of 0.025 mg/d and increasing 
to a maximum total dose of 0.2 mg/d (0.05 mg/[kg·d]) over 
5 days, was initiated, and rifampin administered orally at a 
single, daily dose of 20 mg/kg was added to the treatment 
regimen. Administration of the 5-fluorocytosine was discon-
tinued. 
He continued to receive this combination of iv and intraven-
tricular amphotericin B, in addition to oral rifampin, for the 
next 48 days; cultures of the CSF were repeatedly negative 
during this interval. Antifungal therapy was discontinued, and 
specimens for surveillance cultures were obtained daily from 
his intraventricular drain. Cultures of specimens obtained 4 
and 8 days after discontinuation of therapy were again posi-
tive for A. jitmigatus; therapy with iv amphotericin B, intraven-
tricular amphotericin B, and oral rifampin was resumed. A 
third CT revealed hydrocephalus but no evidence of new or 
residual abscess cavities. The intraventricular drain was 
replaced with an extraventricular drain 10 days later. A cul-
ture of the catheter tip was sterile. Therapy with intraventric-
ular amphotericin B was continued for an additional 14 days, 
while iv amphotericin Band rifampin were administered for 
an additional 46 days. 
The infant received iv amphotericin B for 111 days, intraven-
tricular amphotericin B for 58 days, rifampin for 90 days, and 
5-fluorocytosine for 19 days. Despite surveillance culturing 
of specimens from the extraventricular drain, no more cul-
tures of the CSF yielded pathogens during the next 6 months. 
The patient began receiving low doses of prednisone several 
weeks after cessation of his antifungal therapy. Subsequently, 
his extraventricular drain was replaced with a ventricular-
peritoneal shunt as treatment for residual hydrocephalus. Ther-
apy with cyc1osporine was restarted 6 months after the com-
pletion of his antifungal therapy. He remains asymptomatic 
and has excellent liver function, and no recurrent aspergillo-
sis has become evident. Serial evaluations have revealed evi-
dence of slow developmental progress; the delay in motor 
development has been more severe than that in cognitive de-
velopment. At 20 months of age, he is functioning at the de-
velopmentallevel for ages 6-9 months. It is important to note 
that the neurologic insult in this infant was probably multifac-
torial; evidence of significant impairment had been recognized 
before transplantation. We believe that further insult occurred 
during the episode of shock associated with the CMV infec-
tion and during infection due to an Aspergillus species. 
Discussion 
Cases of invasive aspergillosis have been reported after 
transplantation of the liver [2-6], kidney [1, 7-11], and heart 
[12-15]. Aspergillosis was diagnosed in 9 % of adult liver trans-
plant recipients who received immunosuppressive therapy con-
sisting of administration of azathioprine, prednisone, and 
antilymphocyte globulin [2]. Similarly, 6 % of adult liver trans-
plant recipients treated with cyclosporine and prednisone de-
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those three series of liver transplantations [2-4] died, as did 
an additional five patients from two smaller series [5, 6]. In 
11 of 24 adult liver transplant recipients with aspergillosis, 
involvement of the CNS by the disease was identified during 
the course of infection or at autopsy. In contrast, only 2.7% 
of renal transplant recipients developed aspergillosis [1, 7-11]; 
in 26% of these patients, the disease involved the CNS [1, 
8-10]. Weiland et al. [11 reported a 90% survival rate among 
renal transplant recipients with primary pulmonary aspergil-
losis who were treated with a combination of antifungal agents, 
resection. and. in some cases, cessation of immunosuppres-
sion; however, only one of 12 reported renal transplant 
recipients in whom involvement of the CNS by aspergillosis 
was documented [1, 7-11] has survived. Similar survival rates 
among heart transplant recipients and an occasional survivor 
of pulmonary disease have been reported, but none of such 
patients in whom the aspergillosis involved the CNS survived 
[12-15] . 
The diagnosis of aspergillosis of the CNS was made in our 
patient after he developed focal seizures. The acute develop-
ment of focal neurologic deficits, such as focal seizure or 
hemiparesis. is common in patients with aspergillosis of the 
CNS [16]. These focal findings are thought to be the clinical 
expression of the invasion of blood vessels by Aspergillus or-
ganisms. which subsequently causes thrombosis and hemor-
rhagic infarction. An acute. unexplained infarct may be the 
earliest clue to the presence of aspergillosis of the CNS in 
a high-risk patient. The areas of infarction typicaliy develop 
into either singJe or multiple abscesses involving the cere-
Table 1. Characteristic!' of survivors of aspergi1ichj, of the CNS. 
brum, the cerebellum, and, rarely, the spinal cord. A CT is 
therefore a very important diagnostic tool; it can reveal evi-
dence of both early and late aspergillosis of the CNS. Menin-
geal signs appear to be quite rare, although focal meningitis 
has been observed, especially in association with initial in-
volvement of the sphenoid sinuses by aspergillosis and the 
subsequent contiguous spread to the CNS [16, 17]. Analysis 
of the spinal fluid may reveal complete normality or pleocy-
tosis with increased protein. Uncommonly, CSF obtained by 
lumbar puncture has yielded an Aspergillus species when cul-
tured. 
Factors suspected to favor the development of invasive as-
pergillosis in renal transplant recipients include exposure to 
antilymphocyte globulin, history of bacterial sepsis or pneu-
monia (which perhaps exposes the patients to prolonged an-
tibiotic usage), and CMV infection [1]. The characteristics 
of 50 % of patients reported by Weiland et al. [1] included at 
least two of these factors. Our patient, for whom all three 
of these risk factors were noted, might have been recognized 
as being at high-risk for aspergillosis. 
Survival after aspergillosis of the CNS has been infrequent. 
Table 1 shows the characteristics of reported survivors of this 
disease. Five of the 11 survivors had no history of an under-
lying systemic condition predisposing to invasive aspergillo-
sis. However, two of these patients had sinusitis. Aspergillus 
species are know to occasionally cause sinusitis and to sub-
sequently involve the CNS in immunocompetent patients. The 
absence of any underlying immunologic defect may have been 
an important factor in the recovery of the aforementioned five 
~~~~~~~~~~~~~--~~~~~~~~-------
Af:e of 
[Refer- pallen: Cnd~rlying 
enceJ (Y,I condition 
[17] ~ None 
[18] 1: ALL 
[7] , . Renal transplantation _ ... 
[19] 
-'''' 
Hx iv drug abuse 
[20] 40 None 
[21] 6: "'one 
[22] ::;"7 Sarcoid 
[23] 38 AlcoholIsm 
[24] 4S None 
[25] None 
[PRJ 0.: Liver transplantation 
Aspl'r/iiliw Sae andlor 
snecie~ isoi3.!~'::: typ~ of infection 
!<o: specifie~ Sphenoid sinus; meningitis 
A. fianigaJU5 Pulmonary: right occipital 
brain abscess 
A. fumiFa;us Pulmonary: endopthalmitis and 
brain abscess 
A. or;.':.ae Meningitis 
A. versicolor Left frontal brain abscess 
A. fumigarus :"ung and T2 epidural abscesses 
A. fumigarus \leningitis 
A. fumigarus Right temporal brain abscess 
Not specified \jaxillcr, sinus: right temporal 
brain abs:ess 
A. fumiga/us Skin and ribs: lung and right 
frontal brain abscesses 
A. fumigarus Right parietal brain abscess 
Type of Treatment 
Surgical 
None 
Resection of abscess 
Enucleation 
None 
Resection of abscess 
Resection of abscesses 
None 
Reseclion of abscess 
None 
Resection 0 f ribs and 
abscesses 
Drainage of abscess 
Medical (duration) 
iv ArnB (NA) 
iv AmB and 5-FC (53 d), 
intracavitary ArnB 14 dJ 
iv AmB (I y), intraocular 
ArnE (NA) 




iv ArnB (15 d) 
5-FC (3 mol 
iv AmB (NA) 
iv AmB and 5-FC (NA) 
iv ArnB (35 d) 
iv ArnB (111 d), 
intraventricular AmB 
(58 d), 5-FC (19 dJ, 
rifampin (90 d) 
NOTE. AmB = amphotericin B: NA = not available; ALL = acute lymphoblastic leukemia; 5-FC = 5-ftuorocytosine: Hx = history; PR = present report. 
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patients. Seven of the survivors had a brain abscess due to 
an Aspergillus species. The abscesses were located in the fron-
tal lobe and temporal lobe in two patients each and in the oc-
cipitallobe, parietal lobe, and an unspecified site in one pa-
tient each. In four of the seven patients, the abscesses were 
completely resected; six of the seven were treated with iv am-
photericin B, which was used in combination with 5-fluorocy-
to sine in three patients. 
Of particular interest is the case reported by Burton et a1. 
[7] of the lone survivor of aspergillosis of the CNS after a 
renal transplantation. It is noteworthy that the renal graft also 
remained functional. Treatment in that case consisted of ini-
tial reduction of immunosuppression (the administration of 
azathioprine was discontinued, and that of prednisone was 
reduced to 15 mg/d) and initiation of a 12-month course of 
therapy with iv amphotericin B; no surgical excision was per-
formed. During the last 9 months of treatment, therapy with 
azathioprine was restarted at a dosage of 125 mg/d, and that 
with prednisone was continued at a dosage of 15 mg/d. Am-
photericin was administered at increasing intervals, eventu-
ally as infrequently as one dose every 2 weeks. 
Whereas seven developed a brain abscess, three of the sur-
vivors described in table 1 developed meningitis due to an 
Aspergillus species. Although meningitis caused by an Asper-
gillus species is uncommon, it has been suggested that the 
outcome of patients with meningitis is superior to the out-
come of patients with brain abscesses [17]. The remaining 
patient of the 11 survivors developed a spinal epidural ab-
scess as a direct extension of a primary pulmonary lesion. 
Chemotherapy with a combination of antifungal agents was 
utilized in our case as well as for the treatment of three of 
the survivors identified in the literature review. Initial sup-
port for the use of a combination of chemotherapeutic agents 
for the treatment of fungi originated from an in vitro evalua-
tion of the synergistic action of an1photericin Band 5-fluoro-
cytosine, which showed a tenfold increase in the killing activity 
when the efficacy of the combination of both drugs was com-
pared to that of either drug alone [26]. Further evaluation of 
the in vitro activity of amphotericin B with 5-fluorocytosine 
and with rifampin against isolates of both A. jumigatus and 
Aspergillus fiavus also demonstrated a synergy in inhibition 
but not killing [27]. It is unfortunate that results of antifungal 
susceptibility testing may be erratic [28], thereby raising 
doubts about the significance of the previously mentioned 
findings in regard to efficacy. However, an in vivo evaluation 
with use of a murine model of aspergillosis also demonstrated 
a significant improvement in survival rate when amphoteri-
cin B was used in combination with either 5-fluorocytosine 
or rifampin, in comparison with the survival rate when any 
of the drugs was used alone [29]. Numerous reports of suc-
cessful treatments with use of a combination of chemother-
apeutic agents have been published [30-34], although a recent 
review urged caution in the use of these combinations because 
of the lack of pertinent clinical trials [35]. Given the relative 
infrequency of aspergillosis of the CNS in transplant recipients 
and the unifom1ly poor outcome in such cases, utilization of 
a combination of antifungal agents for chemotherapy seems 
reasonable. 
Concerns about the poor outcome of fungal infections of 
the CNS and the toxicity of amphotericin B have ied to the 
search for alternative antifungal agents. The azole class of an-
tifungal agents offers two possible alternatives. Itraconazole, 
a nitrogen-substituted triazole, has been found to be active 
in vitro against several species of Aspergillus [36, 37]. In vivo 
evaluation with use of a murine model revealed greater activ-
ity than that achieved by ketoconazole, but no comparison 
was made with the activity of amphotericin B [37, 38]. It is 
unfortunate that only a limited number of case repons have 
described the use of itraconazole for the treatment of aspe~­
gillosis in humans, with variable results [39-41]. Flucona-
zole is a newer triazole agent that has been extremely 
promising in the treatment of systemic fungal infection [42 J. 
However, it was tound to be less effective than amphotericin 
B in the treatment of experimental aspergillosis in a rabbit 
model [43], and experience in humans with invasive asper-
gillosis is lacking. Accordingly, administration of neither 
fluconazole nor itraconazole can be recommended as stan-
dard therapy for solid-organ transplant recipients with inva-
sive aspergillosis. 
To the best of our knowledge, our case represents the 
second reported cure of a solid-organ transplant recipient 
with aspergillosis of the CNS and the first reported survival 
of a liver transplant recipient with this disease. Treatment 
strategies included discontinuation of immunosuppression, 
surgical drainage of the abscess, and administration of a 
combination of antifungal agents (including intraventricular 
administration). The fact that the antifungal therapy was begun 
early (for other reasons) for this child may have contributed 
to the successful outcome of the infection. Treatment was con-
tinued for a total duration of 111 days because cultures were 
intermittently positive for pathogens during the first 2 months 
of therapy. The use of surveillance cultures of specimens from 
an intraventricular drain allowed follow-up of the patient for 
recurrences during his treatment and convalescence. His con-
tinued survival and slow but steady developmental progress 
2 years after his infection support the fact that the aspergillus 
infection has been cured. 
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